Dermatology

The Pharmacy Times® Dermatology resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

What can we help you find?
[[thumbnail_alt_text]]
Analysis of care in a routine clinical practice setting show that 40-week treatment of biologic dupilumab (Dupixent, Sanofi-Regeneron) plus noncosmetic topical moisturizer (emollient) is associated with significantly improved symptoms and health-related quality of life (HRQoL) in particular patients with atopic dermatitis (AD).
[[thumbnail_alt_text]]
Data from an analysis of multiple phase 3 studies highlight improvements in mobility, self-care, and usual activities for patients with moderate-to-severe psoriasis taking secukinumab (Cosentyx).
[[thumbnail_alt_text]]
The FDA has approved Ilumya (tildrakizum- ab-asmn) from Sun Pharmaceutical Industries Ltd to treat moderate to severe plaque psoriasis.
[[thumbnail_alt_text]]
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.
[[thumbnail_alt_text]]
Data from 2 phase 3 trials showed significant improvement in disease activity in patients with moderate-to-severe atopic dermatitis treated with baricitinib (Olumiant).
[[thumbnail_alt_text]]
A study of methotrexate in patients with psoriasis found that the immunosuppressive drug was more effective in patients without psoriatic arthritis than those with the added condition.
[[thumbnail_alt_text]]
Patients administered guselkumab achieved an improvement of 90% or more Psoriasis Area Severity Index score than those administered secukinumab.
[[thumbnail_alt_text]]
A new study shows high prevalence of atopic dermatitis among adults, illustrating the need for more available treatment options.
[[thumbnail_alt_text]]
Officials with the FDA have granted Priority Review to dupilumab (Dupixent, Sanofi) for moderate-to-severe atopic dermatitis in adolescent patients aged 12 to 17 years.
[[thumbnail_alt_text]]
If approved for this indication, dupilumab (Dupixent) will be the first systemic biologic medicine to treat adolescents with moderate-to-severe atopic dermatitis.
[[thumbnail_alt_text]]
Sun Pharma announced the availability of its treatment for moderate-to-severe plaque psoriasis in the United States.
[[thumbnail_alt_text]]
Tildrakizumab-asmn (Ilumya) is indicated for the treatment of moderate-to-severe plaque psoriasis in adults.